Enzon Pharmaceuticals Inc (ENZN) Financial Statements (2024 and earlier)

Company Profile

Business Address 20 COMMERCE DRIVE, SUITE 135
CRANFORD, NJ 07016
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments46,98247,64148,1425,4466,5007,478
Cash and cash equivalents46,98247,64148,1425,4466,5007,478
Receivables    4859703,500
Other current assets4058559627094
Other undisclosed current assets   31 7,000(3,500)
Total current assets:47,38747,72648,2325,99314,5407,572
Noncurrent Assets
Nontrade receivables    4859701,940
Deferred income tax assets202   
Total noncurrent assets:202  4859701,940
Other undisclosed assets  28    
TOTAL ASSETS:47,58947,75448,2326,47815,5109,512
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities424403412423517368
Accounts payable331331302324439225
Accrued liabilities93721109978143
Other undisclosed current liabilities 1,275     
Total current liabilities:1,699403412423517368
Noncurrent Liabilities
Total liabilities:1,699403412423517368
Equity
Equity, attributable to parent3,4074,8687,3606,05514,9939,144
Common stock742742742442442442
Additional paid in capital74,70875,98378,00675,69083,64983,649
Accumulated deficit(72,043)(71,857)(71,388)(70,077)(69,098)(74,947)
Total equity:3,4074,8687,3606,05514,9939,144
Other undisclosed liabilities and equity42,48342,48340,460   
TOTAL LIABILITIES AND EQUITY:47,58947,75448,2326,47815,5109,512

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues26701522076,9188,379
Revenue, net8,379
Net investment income      
Gross profit:26701522076,9188,379
Operating expenses(1,058)(1,170)(1,357)(1,180)(1,063)(1,371)
Other undisclosed operating loss      
Operating income (loss):(1,032)(469)(1,305)(973)5,8557,008
Nonoperating income
(Other Nonoperating income)
64671   
Income (loss) from continuing operations before equity method investments, income taxes:(386)(462)(1,304)(973)5,8557,008
Other undisclosed income from continuing operations before income taxes      
Income (loss) from continuing operations before income taxes:(386)(462)(1,304)(973)5,8557,008
Income tax expense (benefit)200(7)(7)(6)(6)(1,563)
Income (loss) from continuing operations:(186)(469)(1,311)(979)5,8495,445
Income (loss) before gain (loss) on sale of properties:(469)(1,311)(979)5,8495,445
Net income (loss) attributable to parent:(186)(469)(1,311)(979)5,8495,445
Preferred stock dividends and other adjustments(1,275)(2,023)(460)   
Net income (loss) available to common stockholders, diluted:(1,461)(2,492)(1,771)(979)5,8495,445

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(186)(469)(1,311)(979)5,8495,445
Comprehensive income (loss), net of tax, attributable to parent:(186)(469)(1,311)(979)5,8495,445

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: